

January 1, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051
Scrip Symbol: SUVENPHAR

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Ref: Scheme of amalgamation of Casper Pharma Private Limited, a wholly owned subsidiary of Suven Pharmaceuticals Limited) into and with Suven Pharmaceuticals Limited under Sections 230 to 232 of the Companies Act, 2013 (“Act”), the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder

Dear Sir/Madam,

This is with reference to, and in furtherance of:

- (a) our letter dated February 29, 2024, regarding the decision of the Board of Directors of Suven Pharmaceuticals Limited approving the Scheme of Amalgamation of Casper Pharma Private Limited (“Transferor Company”) (a wholly owned subsidiary of the Company) into and with Suven Pharmaceuticals Limited (“Transferee Company”) under Sections 230 to 232 of the Companies Act, 2013 (“Act”) and other applicable rules and/or regulations, subject to receipt of applicable regulatory and other approvals (the “Scheme of Amalgamation”);
- (b) our letter dated June 15, 2024 regarding the order dated June 14, 2024 passed by Hon’ble National Company Law Tribunal, Mumbai Bench (“NCLT”), dispensing with the meetings of equity shareholders, secured creditors and unsecured creditors of both the Transferor Company and the Transferee Company;
- (c) our letter dated October 25, 2024 regarding the order pronounced by NCLT, on October 24, 2024 sanctioning the Scheme of Amalgamation.

In this connection, this is to inform that the certified copy of the Order of the NCLT sanctioning the above Scheme of Amalgamation has been filed by the respective companies with the Registrar of Companies, Ministry of Corporate Affairs. In accordance with the terms of the Scheme of Amalgamation, the merger became effective from January 1, 2025 (which is the Effective Date of the merger).

Further, in accordance with the Scheme of Amalgamation, the Appointed Date of the merger is the same as the Effective Date, i.e., January 1, 2025.

Accordingly, Casper Pharma Private Limited, a wholly owned subsidiary of the Company, stands dissolved and amalgamated with the Company, and ceases to be a wholly owned subsidiary of the Company, with effect from January 1, 2025.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

The requisite disclosure in the prescribed format pursuant to Regulation 30 of the SEBI Listing Regulations, read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above has been submitted by the Company on February 29, 2024.

This is for your information and records.

Thanking you.

Yours faithfully,
For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236